Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-370-4081
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable
Genprex (NASDAQ:GNPX) Frequently Asked Questions
What is Genprex's stock symbol?
Genprex trades on the NASDAQ under the ticker symbol "GNPX."
How were Genprex's earnings last quarter?
Genprex Inc (NASDAQ:GNPX) announced its quarterly earnings data on Monday, April, 1st. The company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.10. View Genprex's Earnings History.
When is Genprex's next earnings date?
What price target have analysts set for GNPX?
2 brokers have issued 1-year price targets for Genprex's stock. Their forecasts range from $5.00 to $5.00. On average, they expect Genprex's stock price to reach $5.00 in the next year. This suggests a possible upside of 1,685.7% from the stock's current price. View Analyst Price Targets for Genprex.
What is the consensus analysts' recommendation for Genprex?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genprex.
Has Genprex been receiving favorable news coverage?
Media stories about GNPX stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genprex earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Genprex.
Are investors shorting Genprex?
Genprex saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 107,800 shares, an increase of 349.2% from the October 31st total of 24,000 shares. Based on an average daily trading volume, of 82,400 shares, the short-interest ratio is presently 1.3 days. Currently, 1.2% of the company's stock are sold short. View Genprex's Current Options Chain.
Who are some of Genprex's key competitors?
Some companies that are related to Genprex include Pulmatrix (PULM), Ceapro (CRPOF), BIOLINERX LTD/S (BLRX), AEterna Zentaris (AEZS), Mateon Therapeutics (MATN), PDS Biotechnology (PDSB), Salarius Pharmaceuticals (SLRX), Heat Biologics (HTBX), Adial Pharmaceuticals (ADIL), Regulus Therapeutics (RGLS), Neurotrope (NTRP), Aytu Bioscience (AYTU), Tocagen (TOCA), Acerus Pharmaceuticals (ASPCF) and Guardion Health Sciences (GHSI).
What other stocks do shareholders of Genprex own?
Who are Genprex's key executives?
Genprex's management team includes the folowing people:
- Mr. John Rodney Varner, Co-Founder, CEO, Sec. & Chairman (Age 62)
- Dr. Julien L. Pham M.P.H., M.D., MPH, Pres & COO (Age 42)
- Mr. Ryan M. Confer, Chief Financial Officer (Age 37)
- Dr. Jack A. Roth FACS, M.D., Chairman of Scientific & Medical Advisory Board
Who are Genprex's major shareholders?
Genprex's stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Management LLC (3.64%). Company insiders that own Genprex stock include Jack A Roth, John Rodney Varner and Julien L Pham. View Institutional Ownership Trends for Genprex.
Which institutional investors are selling Genprex stock?
How do I buy shares of Genprex?
Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Genprex's stock price today?
One share of GNPX stock can currently be purchased for approximately $0.28.
How big of a company is Genprex?
Genprex has a market capitalization of $4.44 million. The company earns $-12,370,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. View Additional Information About Genprex.
What is Genprex's official website?
How can I contact Genprex?
Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-370-4081 or via email at [email protected]
MarketBeat Community Rating for Genprex (NASDAQ GNPX)
MarketBeat's community ratings are surveys of what our community members think about Genprex and other stocks. Vote "Outperform" if you believe GNPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNPX will underperform the S&P 500 over the long term. You may vote once every thirty days.
